Catasys Inc. (CATSD)

Terren S. Peizer
Chairman and Chief Executive Officer

Terren S. Peizer is the founder of our company and has served as our chief executive officer and chairman of our Board of Directors since our inception in February 2003. He has served as Managing Director of Socius Capital Partners, LLC, since September 2009. Mr. Peizer has served on the board of Xcorporeal, Inc. since August 2007 and was executive chairman until October 2008. Mr. Peizer also served as chief executive officer of Clearant, Inc., a company which he founded in April 1999 to develop and commercialize a universal pathogen inactivation technology, until October 2003. He served as chairman of its board of directors from April 1999 to October 2004 and as a director until February 2005. In addition, from June 1999 through May 2003 he was a director, and from June 1999 through December 2000 he was chairman of the board, of supercomputer designer and builder Cray Inc., a NASDAQ Global Market company. Mr. Peizer has been the largest beneficial stockholder and has held various senior executive positions with several technology and biotech companies. He has assisted companies by assembling management teams, boards of directors and scientific advisory boards, formulating business and financial strategies, and investor relations. Mr. Peizer has a background in venture capital, investing, mergers and acquisitions, corporate finance, and previously held senior executive positions with the investment banking firms Goldman Sachs, First Boston and Drexel Burnham Lambert. He received his B.S.E. in Finance from The Wharton School of Finance and Commerce.

 

Rick A. Anderson
President and Chief Operating Officer

Richard A. Anderson has more than fifteen years of experience in business development, strategic planning and financial management. He has served as a director since July 2003 and an officer since April 2005. He was the chief financial officer of Clearant, Inc. from November 1999 until March 2005, and served as a director from November 1999 to March 2006.  Mr. Anderson was previously a director and founding member of PriceWaterhouseCoopers LLP’s, Los Angeles office transaction support group, where he was involved in operational and financial due diligence, valuations and structuring for high technology companies. He received a B.A. in Business Economics from University of California, Santa Barbara.

 

Peter Donato
Chief Financial Officer

Peter Donato has nearly 20 years of progressive financial management experience in large, publicly traded companies as well as small, entrepreneurial companies. He began his career in public accounting with Ernst & Young, and most recently served as CFO of Iris International, a NASDAQ traded medical diagnostics equipment manufacturer, and CFO of Gamma Medica-Ideas, an early stage medical imaging company.  He is credited for establishing a strong and timely reporting structure, improved control environment, recruiting and retaining strong accounting, finance and IT teams, as well as developing and maintaining strong relationships with external stakeholders including: investors, coverage analysts, bankers, insurance brokers and auditors.  He has held positions with increasing responsibilities at General Motors, Honda, Scotts-Miracle Gro, and Accellent.  Mr. Donato graduated from The Ohio State University with a BS in Business Administration and earned an MBA from the University of Akron.

 

Gary Ingenito, MD, PhD
SVP of Scientific Affairs

Dr. Ingenito is responsible for preclinical and clinical scientific research and development. He is a member of the senior executive management team, providing strategic direction for future clinical trials, clinical product development, creation of expanded patient treatment algorithms, data analysis and reporting. Dr. Ingenito previously held executive positions at Angiotech, SFBC International, Otsuka Pharmaceuticals, Corning-Besselaar, and Novartis. A neurologist, Dr. Ingenito
received his bachelor’s degree from Johns Hopkins University, an MD from Jefferson Medical College and a PhD in microbiology/cellular immunology from Thomas
Jefferson University.

 

W. Gregory McLane
SVP Sales and Marketing

Mr. McLane is responsible for the overall sales and marketing efforts of the company, encompassing customer acquisition, marketing strategy, market research, member outreach and account management. Prior to joining the company he led the marketing activities for Magellan Health Services and founded Optimized Benefits, Inc., a health benefits company that replaced the one-size-fits-all HMO, PPO and CDHP plans with “Life Stage” plans which address the different needs of employees at various stages of their lives. He also led strategy development and product development for CIGNA and ran consumer products businesses for Procter & Gamble, Campbell Soup and Nabisco. Mr. McLane earned a Bachelor of Science degree from The Wharton School of the University of Pennsylvania with majors in accounting and decision science, and a Masters of Business Administration from Cornell University with concentrations in management and organizational behavior.

 

Lawrence M. Weinstein, MD
SVP of Medical Affairs

Dr. Weinstein leads the clinical initiatives for the development of clinical products and provides medical leadership for the business development, marketing and site management departments. Dr. Weinstein also serves as the primary clinical liaison to licensees, physician groups, corporate affiliations, managed care organizations, insurers and external affairs. Prior to Catasys, Dr. Weinstein held positions at PacifiCare Behavioral Health/United Behavioral Health, Magellan Behavioral Health and the Chemical Dependence Unit at St. Elizabeth’s Hospital in Chicago. He has also worked in private practice providing individual and group diagnostic and psychotherapeutic services, as well as family therapy. Dr. Weinstein received his M.D. from the Ross University School of Medicine, and completed his internship and residency in psychiatry at Michael Reese Hospital and Medical Center in Chicago.